NO324323B1 - Nytt salt av perindopril og farmasoytiske sammensetninger inneholdende det - Google Patents
Nytt salt av perindopril og farmasoytiske sammensetninger inneholdende det Download PDFInfo
- Publication number
- NO324323B1 NO324323B1 NO20030849A NO20030849A NO324323B1 NO 324323 B1 NO324323 B1 NO 324323B1 NO 20030849 A NO20030849 A NO 20030849A NO 20030849 A NO20030849 A NO 20030849A NO 324323 B1 NO324323 B1 NO 324323B1
- Authority
- NO
- Norway
- Prior art keywords
- perindopril
- salt
- pharmaceutical compositions
- compositions containing
- tert
- Prior art date
Links
- IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 title claims description 20
- 229960002582 perindopril Drugs 0.000 title claims description 19
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 14
- 150000003839 salts Chemical class 0.000 title description 14
- 206010019280 Heart failures Diseases 0.000 claims description 3
- 150000004677 hydrates Chemical class 0.000 claims description 3
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims description 3
- 206010020772 Hypertension Diseases 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000000637 arginyl group Chemical class N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims 3
- 239000004480 active ingredient Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical class CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 10
- 150000001483 arginine derivatives Chemical class 0.000 description 9
- 239000003826 tablet Substances 0.000 description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 3
- 159000000000 sodium salts Chemical class 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- 239000005541 ACE inhibitor Substances 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 229940086440 Angiotensin I converting enzyme inhibitor Drugs 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 125000002059 L-arginyl group Chemical class O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 208000037849 arterial hypertension Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- -1 perhydroindole carboxylic acid Chemical class 0.000 description 1
- IYNMDWMQHSMDDE-MHXJNQAMSA-N perindopril erbumine Chemical class CC(C)(C)N.C1CCC[C@@H]2N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H](C(O)=O)C[C@@H]21 IYNMDWMQHSMDDE-MHXJNQAMSA-N 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- REFMEZARFCPESH-UHFFFAOYSA-M sodium;heptane-1-sulfonate Chemical compound [Na+].CCCCCCCS([O-])(=O)=O REFMEZARFCPESH-UHFFFAOYSA-M 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Indole Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0204847A FR2838648B1 (fr) | 2002-04-18 | 2002-04-18 | Nouveau sel de perindopril et les compositions pharmaceutiques qui le contiennent |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20030849D0 NO20030849D0 (no) | 2003-02-24 |
| NO20030849L NO20030849L (no) | 2003-10-20 |
| NO324323B1 true NO324323B1 (no) | 2007-09-24 |
Family
ID=8871521
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20030849A NO324323B1 (no) | 2002-04-18 | 2003-02-24 | Nytt salt av perindopril og farmasoytiske sammensetninger inneholdende det |
Country Status (38)
| Country | Link |
|---|---|
| US (1) | US6696481B2 (xx) |
| EP (1) | EP1354873B1 (xx) |
| JP (1) | JP3737488B2 (xx) |
| KR (1) | KR100542468B1 (xx) |
| CN (1) | CN1211365C (xx) |
| AP (1) | AP1787A (xx) |
| AR (1) | AR039428A1 (xx) |
| AT (1) | ATE271036T1 (xx) |
| AU (2) | AU2003222921A1 (xx) |
| BR (1) | BR0300709A (xx) |
| CA (1) | CA2423825C (xx) |
| CR (1) | CR7576A (xx) |
| DE (1) | DE60300011T2 (xx) |
| DK (1) | DK1354873T3 (xx) |
| EA (1) | EA005676B1 (xx) |
| EC (1) | ECSP045441A (xx) |
| ES (1) | ES2224092T3 (xx) |
| FR (1) | FR2838648B1 (xx) |
| GE (1) | GEP20074211B (xx) |
| HK (1) | HK1057367A1 (xx) |
| HR (1) | HRP20041079B1 (xx) |
| IL (1) | IL164424A (xx) |
| IS (1) | IS2842B (xx) |
| MA (1) | MA27115A1 (xx) |
| ME (1) | ME00454B (xx) |
| MX (1) | MXPA03002346A (xx) |
| NO (1) | NO324323B1 (xx) |
| NZ (1) | NZ524478A (xx) |
| OA (1) | OA12806A (xx) |
| PL (1) | PL359321A1 (xx) |
| PT (1) | PT1354873E (xx) |
| RS (1) | RS51694B (xx) |
| SI (1) | SI1354873T1 (xx) |
| TN (1) | TNSN04206A1 (xx) |
| TR (1) | TR200401793T4 (xx) |
| UA (1) | UA79463C2 (xx) |
| WO (1) | WO2003087050A2 (xx) |
| ZA (1) | ZA200301395B (xx) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2395195A (en) * | 2002-11-18 | 2004-05-19 | Cipla Ltd | Preparation of perindopril from carboxy-protected precursor, & perindopril monohydrates for use as angiotensin converting enzyme (ACE) inhibitors |
| EA011712B1 (ru) * | 2004-03-29 | 2009-04-28 | Ле Лаборатуар Сервье | Способ производства твёрдой фармацевтической композиции |
| SI21800A (sl) | 2004-05-14 | 2005-12-31 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Nov postopek sinteze perindoprila |
| DE602005009918D1 (de) * | 2005-01-06 | 2008-11-06 | Ipca Lab Ltd | Verfahren zur Synthese von (2S,3aS,7aS)-1-(S)-Alanyl-octahydro-1H-2-carbonsäurederivaten und Verwendung in der Synthese von Perindopril |
| DE602005015492D1 (de) * | 2005-03-14 | 2009-08-27 | Servier Lab | Verbessertes verfahren zur aufreinigung von perindopril |
| FR2894825B1 (fr) * | 2005-12-21 | 2010-12-03 | Servier Lab | Nouvelle association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion et les compositions pharmaceutiques qui la contiennent |
| FR2897866B1 (fr) | 2006-02-28 | 2008-04-18 | Servier Lab | Forme cristalline alpha du sel d'arginine du perindopril, son procede de preparation, et les compositions pharmaceutiques qui la contiennent |
| FR2897865B1 (fr) * | 2006-02-28 | 2008-04-18 | Servier Lab | Forme cristalline beta du sel d'arginine du perindopril, son procede de preparation, et les compositions pharmaceutiques qui la contiennent |
| GB0624084D0 (en) * | 2006-12-01 | 2007-01-10 | Selamine Ltd | Ramipril amino acid salts |
| GB0624087D0 (en) * | 2006-12-01 | 2007-01-10 | Selamine Ltd | Ramipril combination salt |
| GB0624090D0 (en) * | 2006-12-01 | 2007-01-10 | Selamine Ltd | Ramipril amine salts |
| SI22542A (sl) * | 2007-06-04 | 2008-12-31 | Diagen D.O.O. | Stabilna formulacija amorfnih soli perindoprila, postopek za njeno pripravo v industrijskem merilu in njena uporaba za zdravljenje hipertenzije |
| AU2009263737B2 (en) * | 2008-06-24 | 2013-10-24 | Mylan Laboratories Ltd. | Novel polymorphic forms of Perindopril (L)-Arginine and process for the preparation thereof |
| AU2009212902A1 (en) * | 2008-09-03 | 2010-03-18 | Apotex Pharmachem Inc. | Amorphous form of an L-arginine salt of perindopril and processes of preparation thereof |
| CN101766598A (zh) * | 2008-12-31 | 2010-07-07 | 东英（江苏）药业有限公司 | 含有培哚普利的药物组合物 |
| GB0910692D0 (en) * | 2009-06-20 | 2009-08-05 | Teva Pharma | Compound |
| SI23149A (sl) | 2009-09-21 | 2011-03-31 | Silverstone Pharma | Nove benzatinske soli ACE inhibitorjev, postopek za njihovo pripravo in njihova uporaba za zdravljenje kardiovaskularnih bolezni |
| FR2961105B1 (fr) * | 2010-06-15 | 2013-02-08 | Servier Lab | Utilisation de l'association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion de l'angiotensine pour le traitement de l'insuffisance cardiaque |
| FR2985512B1 (fr) * | 2012-01-05 | 2014-06-20 | Servier Lab | Procede de preparation du sel de l-arginine du perindopril |
| FR2985511B1 (fr) | 2012-01-05 | 2014-01-03 | Servier Lab | Forme cristalline delta du sel d'arginine du perindopril, son procede de preparation, et les compositions pharmaceutiques qui la contiennent |
| CN103172696B (zh) * | 2012-12-19 | 2014-12-17 | 宁波美诺华药业股份有限公司 | 一种γ晶型的培哚普利精氨酸盐的制备方法 |
| FR3040303B1 (fr) * | 2015-08-27 | 2019-04-05 | Les Laboratoires Servier Suivi Par Sabine Goudeau-Wenger | Composition pharmaceutique comprenant un inhibiteur de la hmg-coa reductase et un inhibiteur eca |
| FR3050380B1 (fr) | 2016-04-20 | 2020-07-10 | Les Laboratoires Servier | Composition pharmaceutique comprenant un betabloquant, un inhibiteur de l'enzyme de conversion et un antihypertenseur ou un ains. |
| EP3842035A1 (en) | 2019-12-23 | 2021-06-30 | KRKA, d.d., Novo mesto | Composition for the preparation of perindopril arginine granules, a method for their preparation and pharmaceutical composition comprising the granules |
| SI26268A (sl) | 2021-11-18 | 2023-05-31 | Zupet Rok | Postopek za pripravo hidratirane oblike perindopril l-arginina |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2503155A2 (fr) * | 1980-10-02 | 1982-10-08 | Science Union & Cie | Nouveaux imino diacides substitues, leurs procedes de preparation et leur emploi comme inhibiteur d'enzyme |
| FR2811320B1 (fr) * | 2000-07-06 | 2002-08-23 | Adir | Nouvelle forme cristalline alpha du sel de tert-butylamine du perindopril, son procede de preparation et les compositions pharmaceutiques qui la contiennent |
-
2002
- 2002-04-18 FR FR0204847A patent/FR2838648B1/fr not_active Expired - Lifetime
-
2003
- 2003-02-17 GE GEAP8501A patent/GEP20074211B/en unknown
- 2003-02-17 ME MEP-2008-688A patent/ME00454B/me unknown
- 2003-02-17 TR TR2004/01793T patent/TR200401793T4/xx unknown
- 2003-02-17 ES ES03290383T patent/ES2224092T3/es not_active Expired - Lifetime
- 2003-02-17 PT PT03290383T patent/PT1354873E/pt unknown
- 2003-02-17 DK DK03290383T patent/DK1354873T3/da active
- 2003-02-17 AP APAP/P/2004/003154A patent/AP1787A/en active
- 2003-02-17 AT AT03290383T patent/ATE271036T1/de active
- 2003-02-17 AU AU2003222921A patent/AU2003222921A1/en not_active Abandoned
- 2003-02-17 SI SI200330002T patent/SI1354873T1/xx unknown
- 2003-02-17 WO PCT/FR2003/000507 patent/WO2003087050A2/fr active Application Filing
- 2003-02-17 DE DE60300011T patent/DE60300011T2/de not_active Expired - Lifetime
- 2003-02-17 UA UA20041109440A patent/UA79463C2/uk unknown
- 2003-02-17 OA OA1200400279A patent/OA12806A/en unknown
- 2003-02-17 EP EP03290383A patent/EP1354873B1/fr not_active Expired - Lifetime
- 2003-02-17 RS YU90904A patent/RS51694B/en unknown
- 2003-02-20 ZA ZA200301395A patent/ZA200301395B/xx unknown
- 2003-02-21 US US10/371,865 patent/US6696481B2/en not_active Expired - Lifetime
- 2003-02-24 NO NO20030849A patent/NO324323B1/no not_active IP Right Cessation
- 2003-02-27 AU AU2003200700A patent/AU2003200700C1/en not_active Revoked
- 2003-02-28 NZ NZ524478A patent/NZ524478A/en not_active IP Right Cessation
- 2003-03-07 CN CNB031071481A patent/CN1211365C/zh not_active Expired - Lifetime
- 2003-03-18 MX MXPA03002346A patent/MXPA03002346A/es active IP Right Grant
- 2003-03-20 KR KR1020030017434A patent/KR100542468B1/ko active IP Right Grant
- 2003-03-21 BR BR0300709-0A patent/BR0300709A/pt not_active Application Discontinuation
- 2003-03-24 PL PL03359321A patent/PL359321A1/xx not_active Application Discontinuation
- 2003-03-25 JP JP2003083250A patent/JP3737488B2/ja not_active Expired - Lifetime
- 2003-04-03 CA CA002423825A patent/CA2423825C/fr not_active Expired - Fee Related
- 2003-04-03 EA EA200300334A patent/EA005676B1/ru unknown
- 2003-04-16 AR ARP030101332A patent/AR039428A1/es not_active Application Discontinuation
-
2004
- 2004-01-10 HK HK04100189A patent/HK1057367A1/xx not_active IP Right Cessation
- 2004-10-05 IL IL164424A patent/IL164424A/en active IP Right Grant
- 2004-10-15 TN TNP2004000206A patent/TNSN04206A1/en unknown
- 2004-10-27 IS IS7516A patent/IS2842B/is unknown
- 2004-11-03 MA MA27926A patent/MA27115A1/fr unknown
- 2004-11-17 HR HRP20041079AA patent/HRP20041079B1/hr not_active IP Right Cessation
- 2004-11-18 EC EC2004005441A patent/ECSP045441A/es unknown
- 2004-11-18 CR CR7576A patent/CR7576A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO324323B1 (no) | Nytt salt av perindopril og farmasoytiske sammensetninger inneholdende det | |
| CN104540836B (zh) | 作为精氨酸酶抑制剂的环约束类似物 | |
| US10167247B2 (en) | Solid forms of treprostinil | |
| CN101921245B (zh) | 抑制碳酸酐酶ⅱ的磺胺类化合物及合成方法与用途 | |
| CN102015725B (zh) | 利福昔明的多种形式及其用途 | |
| CN102812038B (zh) | 胃肠道病症的治疗 | |
| ES2575131T3 (es) | Inhibidores boropéptidos de enteropeptidasa y sus usos en tratamientos de obesidad, sobrepeso y/o enfermedades asociadas con un metabolismo anormal de la grasa | |
| ES2910003T3 (es) | Compuestos y composiciones de cocristal iónico de litio de anión orgánico | |
| JP2014169270A (ja) | （１ｓ，２ｓ，３ｓ，４ｒ）−３−［（１ｓ）−１−アセチルアミノ−２−エチル−ブチル］−４−グアニジノ−２−ヒドロキシ−シクロペンチル−１−カルボン酸水和物の製造方法 | |
| Blough et al. | Alpha-ethyltryptamines as dual dopamine–serotonin releasers | |
| Nin et al. | Biological effects of morpholin-4-Ium 4 methoxyphenyl (morpholino) phosphinodithioate and other phosphorothioate-based hydrogen sulfide donors | |
| Lee et al. | Colon-specific delivery of celecoxib is a potential strategy to improve toxicological and pharmacological properties of the selective Cox-2 inhibitor: implication in treatment of familiar adenomatous polyposis | |
| CN104974141B (zh) | 咔唑四唑类衍生物及其制备方法和应用 | |
| CN102470108A (zh) | 非pH依赖型制剂(6-(5-氯-2-吡啶基)-5-[(4-甲基-1-哌嗪基)羰氧基]-7-氧代-6，7-二氢-5H-吡咯并[3，4-b]吡嗪) | |
| CN105358557A (zh) | 化合物的多晶型物和盐 | |
| RU2008145115A (ru) | Стабильные фармацевтические композиции производственных соединений 2-аза-бицикло[3.3.0]-октан-3-карбоновой кислоты | |
| WO2010111951A1 (zh) | 普拉格雷氢溴酸盐的晶体 | |
| CN106032377A (zh) | 四氮唑类urat1抑制剂、制备方法及其在高尿酸血症和痛风治疗上的用途 | |
| ES2387435B1 (es) | Uso de heptapéptidos para el control de la hipertensión | |
| Phan et al. | Structure-assisted discovery of Variola major H1 phosphatase inhibitors | |
| Gibson et al. | Sickle cell disease and 5HMF: the search for effective treatments | |
| Dulce et al. | Nitroso-redox balance: a key mechanism in the regulation of the myocardial function in health and disease | |
| US20180360810A1 (en) | Nupharidine compounds and derivatives thereof for the treatment of cysteine protease related diseases | |
| PT105914A (pt) | Utilização de um extracto de bagaço de azeitona inibidor da enzima acetilcolinesterase no tratamento de perturbações colinérgicas | |
| FR3027803A1 (fr) | Composition pharmaceutique comprenant un betabloquant et un inhibiteur de l'enzyme de conversion |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1K | Patent expired |